Proptosis Revealing a Rare Lacrimal Gland Tumor: A Case of Chondroid Syringoma in a 35-year-old Patient

Boubacar Efared1,2, Kadre Ousmane Kadre Alio1,3, Boubacar Idrissa2, Aïchatou Balaraba Abani Bako1,3, Habiba Salifou Boureima3, Ali Salèye3 and Nouhou Hassan1
1Faculty of Health Sciences, Abdou Moumouni University, Niamey, Niger. 2Pathology laboratory, Niamey National Hospital, Niamey, Niger. 3General Referral Hospital, Niamey, Niger.

ABSTRACT: Lacrimal gland chondroid syringoma is a very rare tumor with classic clinico-radiological symptoms that should be familiar to clinicians for appropriate patients' management as the tumor has potential for recurrence and malignant transformation. We report herein a case of chondroid syringoma in a 35-year-old patient presenting with progressive painless proptosis for 2 years. He underwent complete surgical removal of the tumor, with subsequent clinical improvement of his symptoms.

KEYWORDS: Proptosis, lacrimal gland, chondroid syringoma, pathology.

Introduction
Lacrimal gland tumors are uncommon, they represent around 12% of orbital tumors according to some reported series.1 Histologically the most frequent lacrimal gland lesions are inflammatory, lymphoproliferative and epithelial respectively.2-4 Pleomorphic adenoma is the main epithelial tumor of the lacrimal gland.3-5 Pleomorphic adenoma is a well known benign tumor commonly found in salivary glands, however it can be found elsewhere with different names: mixed benign tumor or lacrimal gland chondroid syringoma especially in sweat glands.6-8 Lacrimal gland chondroid syringoma (LGCS) is a very rare tumor with quite characteristic clinical and radiological features that could be used for appropriate patient's management as this neoplasm has potential for recurrence and malignant transformation.1,9,10 We report herein additional case of LGCS in a 35-year-old patient who presented with progressive proptosis.

Case Presentation
A 35-year-old male patient presented to hospital for progressive and painless right proptosis for 2 years. At clinical examination, the patient had good general condition, with right proptosis without eye movement limitation or visual disturbances. His visual acuity was 10/10. A cranio-cerebral computed tomography-scan (CT-scan) has been performed. It showed a well circumscribed retro-ocular tumor at the superolateral part of the orbit with no calcifications or bone destruction (Figure 1a and b). The tumor was isodense with no contrast enhancement. The patient underwent surgical resection of the tumor.

The resected nodular specimen measured 3.5 × 3.5 cm with a firm and whitish cut surface (Figure 2). The histopathological analysis showed a well circumscribed tumor with abundant fibrous and chondroid stroma (Figure 3, black arrow) associated with nests of polygonal cells and intercommunicating ductal structures lined with 2 or more rows of polygonal cells. Tubular lumens contain amorphous eosinophilic substance (Figure 3, blue circle), and keratinous cysts are occasionally seen (Figure 4, black arrow). There were no cellular atypia or mitotic figures (Figures 3 and 4). These histopathological features were consistent with lacrimal gland chondroid syringoma (LGCS).

The patient recovered well after surgery with correction of his proptosis and was discharged from the hospital.

Discussion
Lacrimal gland chondroid syringoma (LGCS) is a very rare tumor with quite characteristic clinical and radiological features that should be familiar to clinicians for adequate patients' management.9,10 The tumor is usually found in adult-patients with a mean age around 38 to 47 years, and there is no gender or side predilection.1,5,9 LGCS develops mainly in the orbital lobe of the gland, and patients present with progressive painless proptosis with sometimes axial deviation.5,9,11-13 These symptoms have typically long duration, beyond 10 months.5,9 The present case had these classic clinical features with long duration of about 2 years. The painless symptoms obviously explain why patients seek clinical attention belatedly.

The radiological features of LGCS consist of a well-defined lesion in the lacrimal gland fossa, with no destruction of the surrounding tissues.3,12,14 Calcifications or bone erosions could rarely be associated.9 These stereotypic clinico-radiological features led Rose and Wright9 to propose a score for preoperative diagnosis of LGCS.10 This score is mainly based on the presence or absence of some clinical and radiological signs (on high resolution CT-scan): duration of acute symptoms (less or more than
Clinical Pathology

Figure 1. Cranio-cerebral computed tomography-scan (CT-scan), chondroid syringoma. Note a well circumscribed retro-ocular tumor at the superolateral part of the right orbit with no calcifications or bone destruction (arrows) ((a): coronal view, (b): antero-posterior view).

Figure 2. Gross picture of specimen, chondroid syringoma. A nodular and white-tinged tumor with smooth contours.

Figure 3. Tumor section, chondroid syringoma. Abundant fibrous and chondroid stroma (black arrow) associated with sheets and tubules of epithelial and myoepithelial bland cells. Tubular lumens contain amorphous eosinophilic substance (blue circle) (hematoxylin and eosin stain, ×100).

10 months), persistent pain, sensory loss, well-defined mass, tumor calcifications, bone invasion (Table 1). Patients with long clinical symptoms duration, without pain, with a well circumscribed mass without calcifications and bone destruction, have a strong preoperative suspicion of LGCS. The recommended management of these patients is surgical complete tumor removal without prior biopsy. Malignant preoperative diagnosis is suspected in patients with short symptoms duration, painful, larger and ill-defined masses with calcifications and bone destruction. Incisional preoperative biopsy should be performed in such cases.9

Incomplete resection and subsequent recurrences are predictive of malignant transformation.15-17 Preoperative biopsy is believed to cause tumor cells displacement into surrounding tissues with recurrence risk.9 Hence the recommendation to remove the biopsy track with the tumor in patients with prior biopsies.

Although the score and recommendations of Rose and Wright have a valuable clinical application, they are not always verified. In fact, many preoperative misdiagnoses of LGCS have been reported.1,18 Cases of LGCS may have misleading clinical and radiological presentations (pain, short clinical symptoms, calcifications, bone destructions). Also, some orbital lesions may mimic clinico-radiological features of LGCS, leading to unnecessary or suboptimal surgery.18 On the other hand, the effect of preoperative biopsies on the tumor prognosis (especially recurrences) is controversial.19 Our patient presented with classic clinical and radiological signs, and the
surgical resection of the tumor was performed without prior biopsy.

Histopathological analysis is the only reliable way to achieve a correct diagnosis of LGCS. The histological diagnosis is straightforward although the site is very uncommon. It shows typically a variable admixed amount of epithelial, myoepithelial and stromal tissues. The epithelial cells are arranged in sheets and tubules associated with epithelial cells. Squamous cell metaplasia or cystic changes are not uncommon. The stromal elements show fibrous, chondroid or osseous differentiation. Cells are bland without atypia or significant mitoses. The tumor is well circumscribed by a fibrous capsule. However, focal tumor extensions into the capsule may be observed, justifying the surgical resection of the tumor with a small rim of healthy surrounding tissue. Our patient has well-circumscribed LGCS with focal squamous metaplasia with fibrous and chondroid stroma.

The outcome of LGCS is good after complete surgical resection. Recurrences and malignant transformation are very rare. Sivamani et al. have reported a case of an 84-year-old man who presented with a recurrent chondroid syringoma on the glabella that had been excised 4 years previously.

The malignant transformation of LGCS leads to carcinoma ex pleomorphic adenoma or malignant mixed tumors. A rapidly growing painful mass with orbital destruction is suggestive of malignancy. The histological variants of carcinoma ex pleomorphic adenoma are mainly adenoid cystic carcinoma, mucoepidermoid carcinoma, myoepithelial carcinoma, or squamous cell carcinoma. Carcinoma ex pleomorphic adenoma shows atypia, mitoses and invasion of surrounding tissues. A residual component of LGCS is often seen within the malignant tumor. There are no specific molecular markers for malignant mixed tumor, although they overexpress some cellular proliferation factors like Ki-67 or c-myc along with some genetic alterations that are also found in the benign counterparts (pleomorphic adenomas).

**Conclusion**

Lacrimal gland could rarely be a site of a common histological tumor (chondroid syringoma). This benign tumor presents usually with stereotypic clinico-radiological symptoms that should be familiar to clinicians for better patients' management as the tumor has potential for recurrence and malignant transformation.

**Author Contributions**

BE initiated the study and wrote the manuscript, KOKA and AS performed the surgical management of the patient. All authors revised and edited the manuscript. All authors approved the final version of the manuscript.

**ORCID iD**

Boubacar Efared [https://orcid.org/0000-0002-8623-4005](https://orcid.org/0000-0002-8623-4005)

**REFERENCES**

1. Sen S, Mahindrakar A, Berthia SM, et al. Pleomorphic adenomas of the lacrimal gland: a clinicopathological analysis. *Clin Exp Ophthalmol*. 2004;32: 523–525.
2. Shikishima K, Kawai K, Kitahara K. Pathological evaluation of orbital tumours in Japan: analysis of a large case series and 1379 cases reported in the Japanese literature. *Clin Exp Ophthalmol*. 2006;34:239-244.

3. Ohtsuka K, Hashimoto M, Suzuki Y. A review of 244 orbital tumors in Japanese patients during a 21-year period: origins and locations. *Jpn J Ophthalmol*. 2005;49:49-55.

4. Eldenousky MA, Elbakary MA, Sabik S, et al. Lacrimal fossa lesions: a review of 146 cases in Egypt. *Clin Ophthalmol*. 2014;8:1603-1609.

5. Clarós P, Choffor-Nchinda E, López-Fortuny M, et al. Lacrimal gland pleomorphic adenoma: a review of 52 cases, 15-year experience. *Acta Otolaryngol*. 2019;139:100-104.

6. Kuo Y-L, Tu T-Y, Chang C-F, et al. Extra-major salivary gland pleomorphic adenoma of the head and neck: a 10-year experience and review of the literature. *Eur Arch Otorhino Laryngol*. 2011;268:1035-1040.

7. Zhang P, Tang L-J, Gao H-H, et al. Immunohistochemical features of carcinoma ex pleomorphic adenoma and pleomorphic adenoma in the lacrimal gland. *Int J Ophthalmol*. 2019;12:1238-1242.

8. Binut M, El Fteh A, Persson M, et al. Lacrimal gland pleomorphic adenoma: a rare and morbid malignancy. *Case Rep Otorhinolaryngol*. 2020;2020:1790106.

9. Ashok Kumar P, Paulraj S, Mirchia K, et al. Ductal adenocarcinoma ex pleomorphic adenoma of the lacrimal gland: a rare and morbid malignancy. *Case Rep Ophthalmol*. 2014;12:1125-1133.

10. Tang W, Hei Y, Xiao L. Recurrent orbital space-occupying lesions: a clinicopathologic study of 253 cases. *Chin J Cancer Res*. 2013;25:423-429.

11. Prabhakaran VC, Cannon PS, McNab A, et al. Lesions mimicking lacrimal gland pleomorphic adenoma. *Br J Ophthalmol*. 2010;94:1509-1512.

12. Sivamani R, Wadhwa A, Craig E. Chondroid syringoma: a case report and review of the literature. *Dermatol Online J*. 2006;12:8.